"Evidence-based trials help us prove the efficacy and safety of drug products, this should be applied to our traditional Chinese medicine (TCM) development,” said Dalian Li, academician of the Chinese Academy of Engineering, at an academy seminar recently held by the China Association of Traditional...
This research is archived and therefore no longer available. For further assistance please contact your Customer Success Manager or email ClientEngagementTeam@luxresearchinc.com. Thank you!
News Commentary | July 19, 2021
Biogen's AD drug, Aduhelm, continues to stir controversy, as several private insurers have decided not to cover the high costs of the medication. This includes some affiliates of Blue Cross Blue Shield and even the CMS, despite the FDA's accelerated approval. With pharmaceuticals like Roche and Eli ... Not part of subscription
News Commentary | July 30, 2021
Google‑backed Calico and pharma giant AbbVie are doubling down on tackling aging‑related diseases with this second partnership extension. Twenty early‑stage programs have been developed across oncology and neurodegeneration, with the lead oncology target, which acts at multiple steps in the cancer ... Not part of subscription
Company Profile | December 01, 2021
Regulus Therapeutics was created as a joint venture between Alnylam Pharmaceuticals, an RNAi therapeutics company, and Isis Pharmaceuticals (now known as Ionis Pharmaceuticals), a company focused on anti‑sense technologies and therapeutics, in 2007 Regulus Therapeutics is focused on the ... Not part of subscription